# Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease

> **NCT00408928** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 11 (actual)

## Conditions studied

- Graft-versus-Host Disease

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00408928
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-09
- **Final completion:** 2009-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408928, "Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00408928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*